The genome-editing technology CRISPR has raced from the lab to the bedside, but the biotech companies translating the revolutionary tool into human medicine say they’re not cutting corners or ignoring the ethical implications of rewriting human life.

“Something that, for me, inspires hesitation and pause is that when you edit someone, in some respects, that’s forever,” said Dr. John Leonard, CEO of Intellia Therapeutics, at a STAT Plus event on the future of CRISPR. [Two videos below capture Thursday night’s panel discussions.]

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy